In addition, identification of predictive biomarkers to guide ICB treatment is considered to be a crucial step for improving SCLC clinical outcomes (10), as biomarkers such as PD-L1 expression and tumor mutation burden (TMB) are not predictive of survival with ICB in SCLC (6, 11). Here, CD274 is linked to small cell lung carcinoma.